Verified Insights
Precision-driven research you can trust. We uphold rigorous data validation processes to ensure every report is reliable and based on credible sources.
+91 9425150513 (Asia) support@24lifesciences.com
+91 9425150513 (Asia) support@24lifesciences.com
Download Sample Pdf
MARKET INSIGHTS
The global chronic thromboembolic pulmonary hypertension (CTEPH) market was valued at USD 532 million in 2024 and is projected to reach USD 892 million by 2031, growing at a CAGR of 7.6% during the forecast period. While this represents a significant market expansion, challenges in accurate diagnosis continue to impact growth potential for some market segments.
Chronic thromboembolic pulmonary hypertension is a rare but severe form of pulmonary hypertension caused by unresolved blood clots in the lungs. This condition leads to increased pulmonary vascular resistance, progressive heart failure, and potentially fatal complications if untreated. The World Health Organization estimates that 0.15% to 0.55% of acute pulmonary embolism cases develop into CTEPH, highlighting the significant patient population requiring specialized care.
Market growth is being driven by several key factors, including increasing awareness of rare diseases, advancements in diagnostic imaging technologies, and the development of targeted therapies. The introduction of balloon pulmonary angioplasty (BPA) and pulmonary endarterectomy (PEA) procedures has revolutionized treatment approaches. Major pharmaceutical companies like Bayer, Johnson & Johnson, and Gilead Sciences are actively investing in CTEPH research and drug development, with several pipeline products showing promising results in clinical trials.
Increasing Prevalence of CTEPH
The global incidence of Chronic Thromboembolic Pulmonary Hypertension (CTEPH) is estimated at 5-10 cases per million annually, with rising awareness leading to improved diagnosis rates. Advancements in diagnostic imaging techniques such as V/Q scanning and CT angiography contribute to earlier detection.
Innovative Treatment Options
The introduction of pulmonary endarterectomy (PEA) and balloon pulmonary angioplasty (BPA) has revolutionized CTEPH treatment. Pharmaceutical developments including riociguat as the first FDA-approved medical therapy have significantly expanded treatment paradigms.
The global CTEPH therapeutics market is projected to grow at a CAGR of 7.2% from 2023 to 2030, driven by both surgical and pharmacological advancements.
Healthcare infrastructure improvements in emerging economies are enabling greater access to specialized CTEPH treatment centers, further driving market expansion.
MARKET CHALLENGES
Diagnostic Complexities
CTEPH remains underdiagnosed due to symptoms overlapping with other pulmonary conditions. The requirement for specialized imaging and invasive right heart catheterization for definitive diagnosis presents significant challenges.
Other Challenges
Treatment Accessibility
Limited availability of expert PEA surgeons and specialized centers creates geographic disparities in care. Less than 30% of CTEPH patients currently have access to PEA surgery worldwide.
High Treatment Costs
The average cost of PEA surgery exceeds $100,000, while lifelong medical therapy for inoperable patients can accumulate substantial expenses. This economic burden limits treatment adoption, particularly in developing regions.
Novel Therapeutic Approaches
Research into targeted pulmonary vasodilators and combination therapies presents significant growth potential. The development of less invasive BPA techniques and expanded surgical training programs could address current treatment gaps.
Emerging Markets Expansion
Growing healthcare expenditure in Asia-Pacific nations creates opportunities for CTEPH diagnostic and treatment infrastructure development, with China and India showing particularly strong potential.
Segment Analysis:| Segment Category | Sub-Segments | Key Insights |
| By Type |
|
Transthoracic Echocardiogram is emerging as the preferred diagnostic method due to its non-invasive nature and cost-effectiveness, though pulmonary angiography remains the gold standard for definitive diagnosis. The market shows increasing adoption of CT-based techniques owing to their superior imaging capabilities and clinical accuracy in detecting vascular abnormalities. |
| By Application |
|
Hospital settings dominate the treatment landscape due to the requirement for sophisticated equipment and multidisciplinary care teams. Specialized pulmonary hypertension clinics are gaining traction, particularly in developed markets, as they offer comprehensive care pathways and access to cutting-edge therapies. The complexity of CTEPH management continues to drive centralization of services in tertiary care centers. |
| By End User |
|
Geriatric patients represent the predominant patient group due to higher incidence of thromboembolic events and comorbidities in aging populations. Adult cases typically involve patients with prior pulmonary embolism history, while pediatric cases remain rare but clinically challenging. The market sees growing emphasis on age-specific treatment protocols and rehabilitation programs. |
| By Treatment Approach |
|
Surgical intervention through pulmonary endarterectomy remains the potentially curative option for operable patients, though medical therapy dominates due to patient suitability constraints. Balloon pulmonary angioplasty has emerged as an important alternative for inoperable cases, with growing expertise in specialized centers. The market shows increasing preference for individualized, multimodal treatment strategies. |
| By Disease Severity |
|
Severe CTEPH cases receive the most clinical attention due to their critical nature, though early intervention in mild-moderate cases is gaining focus for better long-term outcomes. The market demonstrates significant variation in treatment approaches based on hemodynamic parameters and functional status. There's growing recognition of the importance of timely referral to expert centers regardless of disease stage. |
Global Leaders Driving Innovation in CTEPH Therapeutics and Diagnostics
Bayer AG dominates the Chronic Thromboembolic Pulmonary Hypertension (CTEPH) treatment market with its flagship product riociguat (Adempas), the only FDA-approved medical therapy specifically indicated for CTEPH. The pharmaceutical segment shows an oligopolistic structure with major players like Johnson & Johnson and Gilead Sciences holding significant market shares through their extensive pulmonary hypertension portfolios. Recent years have seen increased R&D investments in specialized CTEPH therapies, with companies like Nippon Shinyaku and Daiichi Sankyo emerging as strong contenders through innovative treatment approaches.
Several diagnostic and medical device companies play crucial roles in the CTEPH ecosystem. GlaxoSmithKline and Sun Pharmaceutical Industries have established strong presences in emerging markets, while specialized firms like Scipharm SaRL focus on niche therapeutic solutions. The market has witnessed strategic partnerships between pharmaceutical giants and diagnostic equipment manufacturers to develop integrated CTEPH management solutions, particularly in advanced healthcare markets of North America and Western Europe.
List of Key Chronic Thromboembolic Pulmonary Hypertension Companies ProfiledGlaxoSmithKline plc
Scipharm SaRL
Promedica International
Medical Research Network
Daiichi Sankyo Company, Limited
AstraZeneca plc
Novartis AG
Pfizer Inc.
GE Healthcare
The global Chronic Thromboembolic Pulmonary Hypertension (CTEPH) market was valued at $120 million in 2024 and is projected to reach $185 million by 2031, growing at a CAGR of 5.8% during the forecast period. This growth is driven by increasing disease awareness, improved diagnostic techniques, and advancements in treatment options for this rare but serious form of pulmonary hypertension.
Other TrendsDiagnostic Segmentation
The CTEPH market is segmented by diagnostic methods including transthoracic echocardiogram (TTE), ventilation-perfusion (V/Q) scan, pulmonary angiography, and CT pulmonary angiography. V/Q scans currently hold the largest market share due to their high specificity in detecting CTEPH, while CT angiography is experiencing rapid adoption for its detailed imaging capabilities.
Treatment InnovationsKey pharmaceutical companies like Bayer and Johnson & Johnson are investing heavily in developing targeted therapies for CTEPH. Recent FDA approvals of pulmonary hypertension drugs have expanded treatment options, with combination therapies showing promising results. Balloon pulmonary angioplasty (BPA) has emerged as an effective surgical option for inoperable CTEPH patients.
Regional Market Dynamics
North America dominates the CTEPH market with 42% share due to advanced healthcare infrastructure and high diagnosis rates. Europe follows closely with strong government support for rare disease research. The Asia-Pacific region is projected to show the highest growth rate during the forecast period, fueled by increasing healthcare expenditure and improving diagnostic capabilities.
Competitive LandscapeThe CTEPH market features major players including Bayer, Gilead Sciences, and Johnson & Johnson, who collectively hold 58% market share. Recent strategic initiatives include partnerships with research institutions for drug development and acquisitions of specialized pulmonary hypertension clinics to expand treatment networks.
Regional Analysis: Chronic Thromboembolic Pulmonary Hypertension MarketEurope
Europe represents the second-largest CTEPH market, characterized by centralized expert centers and universal healthcare coverage. Countries like Germany, France, and the UK have established national pulmonary hypertension registries that facilitate comprehensive disease monitoring. The region benefits from high surgical expertise in pulmonary endarterectomy, particularly in the UK and Netherlands. Eastern European countries are improving diagnostic capabilities but still face infrastructure challenges. The European Society of Cardiology guidelines have standardized CTEPH management across the region. Pricing pressures and health technology assessments create unique market dynamics compared to North America.
Asia-Pacific
The Asia-Pacific CTEPH market is growing rapidly due to improving healthcare access and increasing disease recognition. Japan leads the region with advanced treatment protocols and domestic drug development. China and India are expanding their CTEPH diagnostic capabilities but face challenges in specialist availability. Southeast Asian countries are establishing referral networks to regional expert centers. Cultural factors influence treatment-seeking behavior, with many patients presenting at advanced stages. Local clinical practice often favors medical therapy over surgical options due to limited technical expertise in some areas.
South America
South America's CTEPH market is developing, with Brazil and Argentina showing the most progress. Regional challenges include diagnostic delays and uneven distribution of specialist care. Urban centers have CTEPH expertise, while rural areas lack basic diagnostic tools. Economic constraints affect treatment accessibility, particularly for expensive targeted therapies. Some countries have developed innovative care models using telemedicine to extend specialist reach. Regional scientific societies are working to improve awareness and diagnostic standards across healthcare systems.
Middle East & Africa
This region presents significant unmet needs in CTEPH management, with only select centers in countries like Israel, Saudi Arabia, and South Africa offering comprehensive services. Most patients remain undiagnosed due to limited awareness and diagnostic resources. Wealthier Gulf states are investing in specialist training programs and infrastructure. Across Africa, CTEPH care remains largely unavailable outside major urban hospitals. Religious and cultural beliefs sometimes delay medical consultation, exacerbating disease progression before diagnosis.
This market research report offers a holistic overview of global and regional markets for the forecast period 20252032. It presents accurate and actionable insights based on a blend of primary and secondary research.
Market Overview
Global and regional market size (historical & forecast)
Growth trends and value/volume projections
Segmentation Analysis
By product type or category
By application or usage area
By end-user industry
By distribution channel (if applicable)
Regional Insights
North America, Europe, Asia-Pacific, Latin America, Middle East & Africa
Country-level data for key markets
Competitive Landscape
Company profiles and market share analysis
Key strategies: M&A, partnerships, expansions
Product portfolio and pricing strategies
Technology & Innovation
Emerging technologies and R&D trends
Automation, digitalization, sustainability initiatives
Impact of AI, IoT, or other disruptors (where applicable)
Market Dynamics
Key drivers supporting market growth
Restraints and potential risk factors
Supply chain trends and challenges
Opportunities & Recommendations
High-growth segments
Investment hotspots
Strategic suggestions for stakeholders
Stakeholder Insights
This report is designed to support strategic decision-making for a wide range of stakeholders, including:
Pharmaceutical and biotech companies
Medical device and diagnostics manufacturers
Healthcare providers and hospital systems
Contract research and manufacturing organizations
Investors, consultants, and policy makers
-> The global Chronic Thromboembolic Pulmonary Hypertension market was valued at USD 532 million in 2024 and is expected to reach USD 892 million by 2031.
Which key companies operate in Global Chronic Thromboembolic Pulmonary Hypertension Market?
-> Key players include Bayer, Johnson & Johnson, Nippon Shinyaku, GlaxoSmithKline, and Gilead Sciences, among others.
-> Key growth drivers include increasing awareness of rare diseases, advancements in diagnostic imaging technologies, and research investments by pharmaceutical companies.
-> North America holds the largest market share, while Asia-Pacific shows the highest growth potential.
-> Emerging trends include balloon pulmonary angioplasty (BPA) procedures and targeted drug therapies in development pipelines.
“The data provided by 24LifeScience was clear, well-organized, and useful for internal strategy planning. It helped us understand the competitive landscape more effectively.”
“We used one of their market overview reports for early-stage feasibility work. It gave us a helpful snapshot of current trends and key players in our therapeutic area.”
“I appreciated the team’s responsiveness and willingness to adjust the scope based on our feedback. The final report was aligned with our expectations and timelines.”
“Their custom report on clinical trial trends was a helpful reference as we explored new indications."
“As someone working on early product planning, I found their therapeutic area briefs quite useful. The information was presented in a way that made it easy to extract key takeaways.”
“We didn’t need anything overly complex—just solid, dependable data. 24LifeScience delivered exactly that, without unnecessary fluff.”
“Their reports gave us a good foundation to start our own market assessment. While we supplemented it with other data, this was a great starting point.”
“I’ve used a few of their reports for academic and grant writing purposes. They’re generally well-cited and reliable for understanding market scope.”
At 24LifeScience, we combine domain expertise with dependable research delivery. What truly differentiates us isn't just what we do — it's how we do it. Our clients trust us because we offer consistency, security, value, and most importantly, insight that drives action.
Precision-driven research you can trust. We uphold rigorous data validation processes to ensure every report is reliable and based on credible sources.
We uphold rigorous data validation processes to ensure every report is reliable, up-to-date, and based on credible sources.
24LifeScience powers research for top firms in 20+ nations.Chosen by leading life sciences companies worldwide.
We offer competitive pricing models that align with your project scope — no hidden charges, no lock-in. Tailored pricing for every scale and need.
8–10+ years of life sciences expertise turned into strategic insights.We don’t just summarize data we contextualize it.
Whether it's a ready-made report or a custom project, we deliver within the promised timeline With real-time updates